100 results about "Interstitial cell" patented technology

The invention discloses a cross-linking preparing method for heart valve prosthesis material, comprising a cross-linker, cross-linking steps and preserving treatment after cross-linking. The method is characterized in that the collected cardiac valve of a pig is timely and appropriately treated and cleaned, and then the cells are completely removed and cleaned, then the obtained cells are cross-linked by quercetin, thus improving the mechanical strength, further eliminating the antigenicity and enhancing the stability. The acellular bioprothesis cardiac valve of the pig adopts heart valve prosthesis prepared by the method has the advantages of non-toxic valve, high tensile strength, resistance to enzymic degradation and minimum release of the cross-linker and self-protein of valves. The cross-linking properties of the acellular bioprothesis cardiac valve made of cardiac valve material of the pig are beneficial to transplanting, proliferation, covering and long-term anti-calcification of interstitial cells of valves of the body of man and vascular endothelial cells after being transplanted into the human body.

An acupuncture-type tissue slice vitrification freezing carrier is composed of a freezing tube with one end being closed and the other end being open, and an acupuncture device. The acupuncture device comprises a needle head and a needle disposed on the needle head and used for threading tissue slices. A section matching with the internal shape and size of the open end of the freezing tube is disposed on the needle head. After the acupuncture device and the freezing tube are combined, the needle is positioned in the freezing tube, and the needle head is adopted as a tube plug of the freezing tube to seal the open end of the freezing tube. A plurality of tissue slices (such as ovary tissue slices and liver tissue slices) can be threaded in a row on the needle at intervals by the carrier so as to be subjected to each operation of the vitrification freezing and storage, and a plurality of sample tissues can be subjected to the vitrification freezing and storage simultaneously, with simple operation and high efficiency, so that the sample tissues can be dehydrated and refrigerated under the same conditions. The storage of the ovary multicellular ingredients (such as the storage of interstitial cells and extracellular matrix ingredients) is superior to the programmed slow freezing and the carrier-free vitrification freezing method.

The invention provides an establishment of humanized three-dimensional intestinal mucosa model and an application thereof. The model improves a traditional Caco-2 monolayer cell model mainly based on normal physiological structure characteristics of small intestinal epithelium, wherein on basis of adding extracellular matrix, the Caco-2 cells are co-cultured with mucus-secreting cells, interstitial cells and immune cells for a period of time to form a three-dimensional intestinal mucosa model being similar with structure and function of the small intestinal epithelium in vivo. By using the model, a membrane permeating capability at small intestine epithelium as well as a metabolism degree of oral drug molecules can be predicted. The model is mainly used for researching transmembrane transportation and absorption, and metabolism process of medicament molecules at the small intestine in vitro.

The invention relates to a space cell robot used for truss in-orbit assembly. The space cell robot consists of interstitial cells, rotating cells, bidirectional interstitial cells, rotating joint cells, claw function cells, a ball head, a passive connecting head, a truss rod, an active connecting head, a groove, and a flange; the interstitial cells and the bidirectional interstitial cells form a connecting unit of the robot, various space cell robot configurations can be formed, the rotating cells and the rotating joint cells form a motion unit of the robot, and the mutual matching of the rotating cells and the rotating joint cells can achieve rotation work of any range in space; and the claw function cells are an end execution unit of the robot, through the synergy matching between the claw function cells and the motion unit, the groove of the active connecting head can be embedded into the flange of the passive connecting head, the assembly work of the truss rod is completed, magnetic automatic locking devices are designed on the active connecting head and the passive connecting head, and the reliability of the connection is ensured.

The invention relates to the field of prevention and/or treatment of calcific aortic valvular disease. The inventors research and find that nobiletin can effectively down-regulate expression of osteogenic differentiation marker genes BMP2 and RUNX2 in valvular interstitial cells, and inhibit calcification of the valvular interstitial cells, thereby inhibiting or delaying valvular calcification, and further provide use of the nobiletin in preparing medicines for prevention and/or treatment of individual calcific aortic valvular disease. The invention provides a new option for non-surgical treatment of the calcific aortic valvular disease.

The invention relates to a separation and storage method of a pouch fat interstitial cell, which comprises the following steps of: cutting to obtain a pouch fat tissue by adopting a surgical knife, extracting an interstitial tissue of the pouch fat tissue and separating the cell by using an adherent method. The culture and amplification method of the pouch fat interstitial cell comprises the following steps of: carrying out large-scale tissue culture by adopting a paper carrier technology, freezing and storing by using a definite and non-specific genetic component and preserving the cell for a long time. Through the separation and storage method, the pouch interstitial cell can be extracted, massively cultured and preserved for a long time; and the cultured interstitial cell can be used for promoting the healing of skin wound, the healing of diabetic ulcer, the repair of myocardial injury and the repair of hepatic injury.

Provided herein are urine progenitor cells and methods for producing a culture of urine progenitor cells from a urine sample. The cells may be selected based upon the use of a selective cell medium, based upon morphology, and/or by selecting cell-specific markers. Also provided is an isolated urine progenitor cell that is c-kit positive and can differentiate into urothelium, smooth muscle, endothelium or interstitial cells. Methods of use of urine progenitor cells are provided, wherein cell are seeded onto a tissue scaffold are provided. Methods of treating a subject in need thereof are also provided, including providing a bladder tissue substrate that includes differentiated UPCs and transplanting the substrate into the patient. Finally, kits are provided that include a container suitable for the transport of a urine sample; media; one or more antibiotics; a package for holding said container, media, and antibiotics; and optionally, instructions for use.

Aortic valve stenosis (AS) is a chronic process related to a progressive mineralization of the aortic root and valve cusps. We found in human AS valves a high level of expression and enzymatic activity of ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP-1), which correlated to the degree of mineralization. In vitro, inhibition of ENPP activity with ARL 67156 significantly reduced calcification of isolated valve interstitial cells. In a rat model of cardiovascular calcification, ARL 67156 significantly reduced calcification of the aortic root and valve cusps. This is the first study to demonstrate that increased expression and activity of ENPP-1 promotes the mineralization process in AS valves. Hence, inhibition of ectonucleotidase may represent a novel target of therapy for this frequent and serious cardiovascular disease.

The invention discloses a culturing method for improving the in-vitro differentiation phenotype and function of hepatic cells. The culturing method is characterized by comprising the following steps that the hepatic cells are adopted as seed cells, a porous silk protein scaffold is taken as an in-vitro culturing carrier of the hepatic cells, the hepatic cells, hepatogenic interstitial cells and an extracellular matrix are inoculated to the porous silk protein scaffold according to a certain proportion, and the porous silk protein scaffold is put in a simulated hepatic cell in-vitro culturing environment to be cultured. A three-dimensional hepatic cell co-culturing system built through the method not only can be applied to tissue-engineered hepatic cell function units, but also can be applied to in-vitro evaluation of an influence of drugs on a hepatic metabolism enzyme and hepatic toxicity detection, and therefore a novel screening and evaluating tool is supplied to new drug research and development.

The invention discloses a preparation method of an adriamycin-dipeptide compound. Dipeptide or polypeptide containing proline residue is connected to amino of the adriamycin by the acylation through the technique of peptide modification; the toxicity of the adriamycin can be reduced and at the same time the pro-drug can release the adriamycin under the action of tumor interstitial cells so as to ensure that the adriamycin can enrich around tumor tissue to improve the selectivity of the adriamycin to the tumor tissue. The preparation method of the invention has the advantages of fast reaction rate, short term, relatively high productive rate and purity.

The pericardial heart valve replacement (1) is constructed from living tissue of autologous pericardium containing living pericardial interstitial cells (PICs) and a living extracellular matrix (ECM) in the following way: in the first step the size and shape of the patient's native pathological heart valve is determined using real-time three-dimensional transesophageal echocardiography (TEE) or computer tomography (CT angiography) or magnetic resonance imaging (MRI); in the next step a stented (2) or a stentless pericardial heart valve replacement (1) is constructed from a single sheet of living autologous pericardium obtained from the patient; the size and shape of the pericardial heart valve replacement (1) corresponds to the size and shape of the patient's native heart valve and aortic or pulmonary root. The subject matter of the invention also includes the development of a device (5) for the conditioning and modification of the living autologous pericardial heart valve replacement (1) consisting of a ipulsatile pump (6) driving the flow of culture medium in the device (5) to perfuse the cells in the pericardium, a reservoir (7) regulating the fluid capacitance and function of the pericardial heart valve replacement (1), a chamber (8) containing a holder (9) for the placement of the pericardial heart valve replacement (1) during dynamic conditioning, and a gas exchanger (10a, b) for perfusing C0₂ into the culture medium. The reservoir (7), the chamber (8) and the gas exchanger (10a, b) are placed in an incubator (11) with an inner atmosphere of air mixed with 5% C0₂ and a temperature of 36 to 37° C., the individual components of the device (5) being connected by tubing (12).

The invention belongs to the technical fields of biomedicine technology and nanomedicine, and discloses a tumor-targeted liposome drug delivery system with three drugs co-loaded. A multifunctional drug delivery system which actively targets tumors is prepared by the steps that cationic liposome is used as a basic carrier, anti-inflammatory drugs and anti-tumor drugs are loaded in the liposome at the same time, a transmembrane anti-inflammatory peptide is covalently linked to the surface of the liposome, and then the outer layer of the cationic liposome is coated with hyaluronic acid. The liposome simultaneously has the functions such as targeted accumulation and deep penetration of tumor tissue, specific recognition of tumor cells and efficient uptake of the tumor cells and interstitial cells thereof. The multifunctional liposome carrier can co-deliver the transmembrane anti-inflammatory peptide, the anti-inflammatory drugs and the anti-tumor drugs to the tumors, fully exerts the synergistic therapeutic effect of the combined drugs, blocks the key signaling pathways of excessive activation of the tumor cells and the interstitial cells, can reduce the level of inflammation and immunosuppression in the tumors, destroy tumor microenvironment, cuts off tumor cell migration pathways, and finally clears the tumor cells and tumor stem cells.

The invention provides an economic, simple and convenient lung organ culture method and an experimental model, and relates to the technical field of biology. The method comprises the following steps: marking a transgenic mouse with pulmonary epithelial cells by using GFP (Green Fluorescent Protein), sorting the pulmonary epithelial cells and interstitial cells by using a flow cytometry, then co-culturing the sorted lung epithelial cells and mesenchymal cells in an upper-layer small chamber and a lower-layer small chamber divided by Transwell, and promoting the epithelial cells in the upper-layer small chamber to grow and develop into lung organs by using growth factors and biological components secreted by the mesenchymal cells in the lower-layer small chamber. According to the method of the invention, the natural growth environment and mode of in-vivo cells are simulated, and the lung bronchial organ can be obtained under the condition that exogenous growth factors are not added. The mouse lung organ can be used as the experimental model, and can be used for research on lung development process, cell differentiation, lung toxicology, drug screening, organ regeneration and transplantation, etc.

The invention relates to CD146 and antibody diagnosis thereof, and an application thereof in treating triple negative breast cancers. For a first time, the invention provides that CD146 is a novel target of triple negative breast cancer, and an anti-CD146 antibody might become a novel targeting medicine for treating the disease. Therefore, the invention provides an application of CD146 or anti-CD146 antibody or a functional form of the antibody in preparing medicines used for diagnosing and/or treating triple negative breast cancers. CD146 molecules are subjected to specific high expression in triple negative breast cancer tissues, and induce the occurrences of transformation of epithelial cell to mesenchymal cell in tumor cells. Therefore, tumor invasion migration is promoted. Therefore, the mechanism for CD146 antibody to treat triple negative breast cancer is mainly that the CD146 antibody inhibits the mesenchymal cell characteristics of triple negative breast cancer, and reduces the metastasis invasion capacity thereof. Compared with common chemotherapy medicines, the anti-CD146 antibody has the advantages of low side effects and clear target. The anti-CD146 antibody does not cause whole-body side effect.

A compound medicine for arresting bleeding is characterized in that the compound medicine is a mixture of a batroxobin and an interleukin-11; the clinical dosage of the batroxobin is 0.01-10u and that of IL-11 is 0.06-50mg; the batroxobin is the batroxobin from snake venom of Brazilian spearhead adder, white-eyebrow adder or acutus adder, or the batroxobin from recombinant Brazilian spearhead adder, white-eyebrow adder or acutus adder obtained by genetic engineering; the interleukin-11 is produced by human bone-marrow stromal cells (fibroblasts) and interstitial cells, or the recombinant IL-11 by genetic engineering. The medicine for arresting bleeding can not only ensure the curative effect but also decrease the amount of protease so as to reduce the rate of adverse immune response.

The invention relates to an extraction analysis and application method of mair-cona active constituents. The extraction analysis and application method of the mair-cona active constituents belongs to the technical field of bioengineering technology and comprises the following steps of (1) preparation of a mair-cona total extract; (2) preparation of five polarity extracts; (3) analysis of the mair-cona extract on DPPH free radical scavenging ability; (4) analysis of the mair-cona extract on testis interstitial cell proliferation and the function in promoting testis to prohibit cells from secreting testosterone; (5) analysis of monoamine oxidase immunocompetence in the mair-cona extract; (6) analysis of the acetylcholin esterase function in the mair-cona extract; (7) analysis of the anti-Glu-SY5Y damage function in the mair-cona extract. According to the extraction analysis and application method of the mair-cona active constituents provided by the invention, active parts of the mair-cona extract are analyzed, the best therapeutic effects of the active constituents on different diseases are obtained, the application of the mair-cona active constituents is promoted, and meanwhile, an effective reference is provided for orientating function development and chemical separation of mair-cona.

The invention relates to the field of cell cultivation and in particular relates to a separation and purification method of testicular interstitial cells of a naked mole rat. The interstitial cells of the naked mole rat are separated and purified by adopting enzymatic digestion and a Percoll continuous density gradient method. The method provided by the invention can obtain a lot of testicular interstitial cells of the naked mole rat with normal functional activity simply, efficiently and economically, and cultivation under a low oxygen condition can ensure that the cells still can keep the biological characteristics in an in-vivo state in an in-vitro environment, so that the special physiological functions of the testicular interstitial cells of the naked mole rat can be conveniently and directly researched in a pure in-vitro cell cultivation model further, thereby providing an important theoretical basis for exploring the biological mechanism and applying the same to the clinical related fields.

The invention belongs to the technical field of cell culture and particularly relates to a method for inducing differentiation of embryonic stem cells into the liver tissue structure. E-cadherin genes serve as exogenous genes to transfect the embryonic stem cells, and high-efficiency expression embryonic stem cells of the E-cadherin genes are obtained; then, culture and differentiation are conducted to obtain an embryoid body, the embryoid body is transplanted into a three-dimensional cell culture system containing an EMT inhibitor for induced culture, and the three-dimensional growing liver tissue structure is obtained. According to the method, ESC in-vitro liver tissue structure differentiation is researched in the perspectives of cell adhesion and the EMT level for the first time, the expression level is stably controlled after E-cadherin transfection, and enough cell adhesion can be kept in cell differentiation, and the cells can not be dispersed into monolayer cells easily. The excessively quick EMT level of the embryonic stem cells in-vitro differentiation is reduced, synchronous differentiation of differentiated parenchymal liver cells and hepatic interstitial cells is controlled to form liver tissue, and the method meets the requirement of an in-vivo tissue development mechanism better.

This invention describes a process for producing a streptokinase r-SK, comprising the steps of: a) under appropriate expression conditions, cultivating colibacillus engineering cells that carry an expression carrier selected from the following group: the carrier that contains arabinose-induced promoters, or the carrier that not only contains arabinose-induced promoters but also possess the function of directing the targeting proteins to interstitial cells. The coding sequence of the streptokinase is inserted into the expression carrier in order to express soluble and highly active r-SK; b) separating and purifying the step a) wherein said r-SK. In the process of this invention, the expression amount is high, and the separation and purification steps are simple. This invention also describes corresponding expression carriers and engineering cells.

The invention relates to the field of prevention and/or treatment of CAVD. The inventor finds that caffeic acid phenethyl ester (CAPE) can effectively down-regulate the expression of osteogenic differentiation marker genes RUNX2 and ALP in valvular interstitial cells to inhibit the calcification of the valvular interstitial cells, thereby suppressing or delaying the valve calcification; and thus application of caffeic acid phenethyl ester in preparation of the medicine for preventing and/or treating the individual CAVD is provided. Therefore, novel selection is provided for treating the CAVD by using a non-surgical method.